Researchers have identified low-abundance urinary biomarkers that are potentially useful for diagnosing lupus nephritis (LN), according to a new study published in Arthritis & Rheumatology.

The researchers identified these biomarkers using a new technique, an electrode-coupled immunoassay with an electrochemiluminescence (ECL) signal, that is more sensitive than traditional ELISA or antibody-based arrays.

Using a preexisting 40-plex ECL panel, Chandra Mohan, MD, PhD, from the Department of Biomedical Engineering at the University of Houston, Texas, and colleagues analyzed 48 human urine samples from 2 independent cohorts each consisting of 8 patients with active LN and 8 with inactive LN and 8 healthy control patients.


Continue Reading

They found 17 urinary proteins that were elevated in the active LN samples compared with samples from patients with inactive LN and healthy control patients in 1 cohort, and 9 that were similarly elevated in the other cohort. From these, the investigators chose the cytokines interleukin (IL)-7, Il-12p40, and IL-15 and the chemokines IP-10 and TARC for further validation. These 5 biomarkers were undetectable by ELISA.

The investigators developed a custom 5-plex ECL panel, which they used to validate the results from the initial 40-plex screening panel.

Related Articles

The 5 biomarkers again were significantly elevated in active LN compared with inactive LN and healthy control patients.

In addition, all 5 proteins were more frequently elevated in LN compared with other chronic kidney disease controls.

“In conclusion,” the authors wrote, “custom [ECL]-based multiplex immunoassay panels are a promising technology for the identification and validation of potential urinary biomarkers of [LN].”

follow @RheumAdvisor

Reference

Stanley S, Mok CC, Vanarsa K, et al. Identification of low-abundance urinary biomarkers in lupus nephritis using electrochemiluminescence immunoassays [published online January 7, 2019]. Arthritis Rheumatol. doi: 10.1002/art.40813